Moreover, the G proteincoupled receptor 55 (GPR55) and G protein-coupled receptor 119 (
GPR119) are currently being postulated as new members of the cannabinoid receptor family (47) as they have recently been identified as being targets for the endocannabinoids.
Global Markets Direct's, 'Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016', provides in depth analysis on Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics.
The report provides comprehensive information on the Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report provides a snapshot of the global therapeutic landscape for Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)
will be presenting a 30-minute scientific presentation entitled "Creating and Using a Physiological Model to Support Development of a
GPR119 Agonist Diabetes Therapy." The presentation will describe the development, testing, and use of a custom-designed Diabetes PhysioPD model, including use of the model to clarify mechanisms of action, support compound selection, select First-In-Human doses, and predict longer-term (HbA1c lowering) clinical outcomes.